The Analyst Landscape: 6 Views on Silence Therapeutics – Silence Therapeutics (NASDAQ: SLN)

Analyst Ratings for Silence Therapeutics SLN over the last quarter vary from bullish to bearish, according to 6 analysts.

The table below provides an overview of their recent ratings, showing how sentiments have changed over the past 30 days and comparing them to previous months.

	Bullish	A little bullish	Indifferent	A little bearish	Bearish
Total scores	5	1	0	0	0
Last 30 days	1	0	0	0	0
There are 1 million	2	0	0	0	0
There are 2 million	2	1	0	0	0
There are 3 million	0	0	0	0	0

Analyst ratings of 12-month price targets offer additional insight, presenting an average target of $64.5, with a high estimate of $75.00 and a low estimate of $42.00. Holding firm without variation, the current average remains at the level of the previous average price target.

Breaking down analyst ratings: a detailed look

Silence Therapeutics’ standing among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below highlights top analysts, their recent ratings, and adjustments to ratings and price targets.

Analyst	Analyst firm	Action taken	Rating	Current price target	Previous price target
Patrick Trucchio	HC Wainwright & Co.	Maintains	Buy	$75.00	$75.00
Patrick Trucchio	HC Wainwright & Co.	Maintains	Buy	$75.00	$75.00
Patrick Trucchio	HC Wainwright & Co.	Maintains	Buy	$75.00	$75.00
Patrick Trucchio	HC Wainwright & Co.	Maintains	Buy	$75.00	$75.00
Keay Nakae	Chardan Capital	Maintains	Buy	$42.00	$42.00
Michael Ulz	Morgan Stanley	Maintains	Overweight	$45.00	$45.00

Key ideas:

• Action taken: In response to changing market dynamics and company performance, analysts update their recommendations. Whether they “maintain,” “increase,” or “decrease” their position signifies their response to recent developments related to Silence Therapeutics. This offers insight into analyst views on the current state of the company.
• Rating: By disclosing information, analysts provide qualitative information about stock performance, from “outperform” to “underperform.” These ratings reflect expectations regarding the relative performance of Silence Therapeutics compared to the market as a whole.
• Price targets: Analysts evaluate price target dynamics, providing estimates of the future value of Silence Therapeutics stock. This comparison reveals how analysts’ expectations have changed over time.

Evaluating these analyst ratings along with crucial financial indicators can provide a comprehensive overview of Silence Therapeutics’ position in the market. Stay informed and make smart decisions with the help of our scorecard.

Stay up to date on Silence Therapeutics analyst ratings.

If you want to follow the news and performance of small-cap stocks, you can start by following them here.

Everything you need to know about Silence Therapeutics

Silence Therapeutics PLC is a biotechnology company focused on the discovery and development of novel molecules incorporating short-interfering ribonucleic acid. its pipeline products are: SLN360 therapy designed to temporarily block the message of a specific gene that would otherwise trigger an adverse effect. By silencing the LPA gene, Lp(a) levels are lowered, which in turn should reduce the risks of heart disease, heart attacks and strokes, and the SLN124 treatment aims to temporarily silence TMPRSS6 , a gene that prevents liver function. from the production of a particular hormone that controls iron levels in the body, hepcidin. As hepcidin increases, iron levels in the blood should decrease, which could increase the production of healthy red blood cells, thereby reducing anemia.

Key indicators: financial health of Silence Therapeutics

Market capitalization analysis: Falling below industry benchmarks, the company’s market capitalization reflects a reduced size relative to its peers. This positioning may be influenced by factors such as growth expectations or operational capacity.

Increase in income: The remarkable performance of Silence Therapeutics in 3 months is evident. As of March 31, 2024, the company had achieved an impressive revenue growth rate of 9.07%. This means a substantial increase in the company’s net profit. Compared to its industry peers, the company is lagging behind with a lower growth rate than the average of its healthcare industry peers.

Net margin: Silence Therapeutics’ financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -15.12%, the company has strong profitability and effective cost management.

Return on Equity (ROE): Silence Therapeutics’ ROE exceeds industry standards, highlighting the company’s exceptional financial performance. With an impressive -2.66% ROE, the company uses shareholders’ equity efficiently.

Return on Assets (ROA): Silence Therapeutics’ ROA exceeds industry standards, highlighting the company’s exceptional financial performance. With an impressive -1.3% ROA, the company uses its assets efficiently for optimal returns.

Debt Management: Silence Therapeutics’ debt ratio is lower than the industry average. With a report of 0.0the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.

The Heart of Analyst Ratings: What Every Investor Should Know

Analysts work in banking and financial systems and typically specialize in reporting on defined stocks or industries. Analysts can attend conference calls and corporate meetings, research company financial statements, and communicate with insiders to issue “analyst notes” on stocks. Analysts typically rate each stock once a quarter.

Some analysts publish their forecasts on metrics such as growth, earnings, and revenue estimates to provide additional guidance on their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and only offer their opinions to investors.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.